MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

VBI Vaccines Company Profile (NASDAQ:VBIV)

Consensus Ratings for VBI Vaccines (NASDAQ:VBIV) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for VBI Vaccines (NASDAQ:VBIV)
Show:
DateFirmActionRatingPrice TargetActions
5/7/2015Noble FinancialInitiated CoverageBuy$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/24/2014 forward)
Earnings History for VBI Vaccines (NASDAQ:VBIV)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for VBI Vaccines (NASDAQ:VBIV)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for VBI Vaccines (NASDAQ:VBIV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for VBI Vaccines (NASDAQ:VBIV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
8/14/2015Perceptive Advisors LlcMajor ShareholderBuy650,000$2.08$1,352,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2013Murray George SmithCFOBuy3,027$1.13$3,420.51View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2013Murray George SmithCFOBuy8,973$1.17$10,498.41View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for VBI Vaccines (NASDAQ:VBIV)
DateHeadline
06/23/16 09:39 AMVBI Vaccines Begins Enrolling Patients in a Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate
06/21/16 07:38 AM8:38 am VBI Vaccines closes private placement of ~3.27 mln shares of common stock at ~$4.16/share for total gross proceeds of ~$13.6 mln -
06/21/16 07:30 AMVBI Vaccines Announces Closing of $13.6 Million Private Placement - [Marketwired] - VBI Vaccines , today announced the closing of an equity private placement financing led by OPKO Health and Perceptive Advisors, with participation by ARCH Venture Partners. In accordance with Toronto Stock ...
06/17/16 07:39 AMVBI Vaccines Announces Medulloblastoma Immunotherapy Program - [at noodls] - Sci-B-Vac is a third-generation licensed hepatitis B ('HBV') vaccine currently approved for use in Israel and in 14 other countries. Sci-B-Vac has demonstrated safety and efficacy in over 300,000 patients. ...
06/17/16 07:30 AMVBI Vaccines to Present at the Virus-Like Particle and Nano-Particle Vaccines Conference - [Marketwired] - VBI Vaccines Inc. is scheduled to present at the Virus-Like Particle and Nano-Particle Vaccines Conference on Friday, June 24 at 9:00 AM CEDT . The event is being held at the Leiden University Medical ...
06/11/16 10:00 AMVBI Vaccines to Host Hepatitis B Key Opinion Leader Meeting
06/03/16 07:50 PMVBI Vaccines to Present at the BIO International Convention
05/27/16 07:30 AMVBI Vaccines to Present at the Jefferies Healthcare Conference - [Marketwired] - VBI Vaccines Inc. is scheduled to present at the Jefferies 2016 Healthcare Conference on Friday, June 10 at 2:30 PM ET. The event is being held at the Grand Hyatt New York in New York City.
05/09/16 04:14 PMVBI VACCINES INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Dispos -
05/09/16 02:28 PMAdditional Details Relating to the SciVac Therapeutics and VBI Vaccines Merger Transaction - [at noodls] - CAMBRIDGE, Mass., April 28, 2016 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) ('VBI') is scheduled to present at the Bloom Burton Healthcare Investor Conference on Monday, May 2 at 1:30 PM ET. The ...
04/28/16 07:54 AMVBI Vaccines to Present at the Bloom Burton Healthcare Investor Conference - [at noodls] - New Data Supports the Use of VBI's eVLP Vaccines in Combination with Checkpoint Inhibitors CAMBRIDGE, Mass., March 29, 2016 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) ('VBI') is scheduled to present ...
04/14/16 07:49 AMVBI Vaccines and SciVac Therapeutics Announce Effectiveness of Registration Statement on Form F-4 - [at noodls] - CAMBRIDGE, Mass., March 07, 2016 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) ('VBI') today will present new data supporting its glioblastoma multiforme ('Glioblastoma' or 'GBM') cancer immunotherapy ...
03/30/16 03:55 PMVBI VACCINES INC. Files SEC form 8-K, Other Events -
03/29/16 07:37 AMVBI Vaccines to Present at the World Vaccine Congress Washington - [at noodls] - CAMBRIDGE, Mass., March 03, 2016 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) ('VBI') is scheduled to present at the 28th Annual ROTH Conference on Tuesday, March 15th, 2016 at 5:30 PM PT (8:30 ...
02/26/16 01:13 PMVBI Vaccines: Changing The Game In Vaccines - VBI Vaccines Inc's (O:VBIV) two technology platforms are designed to address hurdles in traditional vaccine design and production. The enveloped virus-like particle (eVLP) vaccine platform allows for the design of eVLP vaccines that closely mimic the ...
02/26/16 01:13 PMVBI Vaccines Inc : 3 Stocks That Should be in Your Portfolio Today - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com. VBI Vaccines (Nasdaq: VBIV) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved ...
02/26/16 05:36 AMVBI VACCINES INC. Files SEC form 10-K, Annual Report -
02/17/16 08:29 AMGlaxoSmithKline Partners With VBI Vaccines, SciVac To Eliminate Cold Chain - [Accesswire] - NEW YORK, NY / ACCESSWIRE / February 17, 2016 / On February 8, a subsidiary of VBI Vaccines Inc. (NASDAQ: VBIV) called Variation Biotechnologies closed a deal with GlaxoSmithKline (NYSE: GSK) that will ...
02/10/16 11:45 AMBiotech Stocks to Buy in a Down Market - [Accesswire] - NEW YORK, NY / ACCESSWIRE / February 10, 2016 / The markets have been choppy to say the least amid oil price volatility and investors looking ahead to testimony from Janet Yellen. The Dow Jones industrial ...
02/09/16 07:33 AMVBI VACCINES INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial -
02/09/16 07:30 AMVBI Vaccines Announces Research Collaboration with GlaxoSmithKline to Enhance Vaccine Stability - [GlobeNewswire] - CAMBRIDGE, Mass., Feb. 09, 2016-- VBI Vaccines Inc. has entered into a research collaboration with GlaxoSmithKline Biologicals SA to evaluate VBI’ s LPV™ Platform. VBI’ s LPV Platform is a proprietary ...
02/04/16 07:30 AMVBI Vaccines Partners with the Canadian CMV Foundation to Raise Congenital Cytomegalovirus Awareness - [GlobeNewswire] - CAMBRIDGE, Mass., Feb. 04, 2016-- VBI Vaccines Inc. is proud to announce its continued sponsorship support of Le Classique, the Canadian CMV Foundation’ s largest annual fundraiser. Now in its fourth year, ...
01/26/16 07:49 AMVBI Vaccines to Present at the BIO CEO & Investor Conference - [at noodls] - CAMBRIDGE, Mass., Nov. 25, 2015 (GLOBE NEWSWIRE) -- VBI Vaccines (Nasdaq:VBIV) ('VBI') is scheduled to present at the Eighth Annual LD Micro Conference on Thursday, December 3, 2015 at 1:30 PM ET (10:30 ...
01/18/16 07:42 AMVBI Vaccines to Present at the Noble Financial Emerging Growth Investor Conference - [at noodls] - CAMBRIDGE, Mass., Nov. 20, 2015 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) ('VBI') today presented an update and new data supporting its glioblastoma multiforme ('Glioblastoma' or 'GBM') cancer ...
01/15/16 07:33 AMVBI VACCINES INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
12/22/15 07:33 AMVBI VACCINES INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits -
12/11/15 03:06 PMVBI VACCINES INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Of -
12/08/15 12:17 PMVBI VACCINES INC. Financials -
12/03/15 11:59 AMINVESTOR ALERT: December's Trending Biotech Stocks - [Accesswire] - CORAL GABLES, FL / ACCESSWIRE / December 3, 2015 / Biotechnology stocks have had their fair share of bumps and bruises after heavy concern surrounding pricing was brought up by several presidential candidates ...
11/25/15 07:45 AMVBI Vaccines to Present at the LD Micro Conference - [at noodls] - CAMBRIDGE, Mass., Nov. 6, 2015 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) ('VBI') is scheduled to present at the 16th Annual World Vaccine Congress Europe on Tuesday, November 10th, 2015 at 6:30 ...
11/20/15 07:46 AMVBI Vaccines Presents Update and New Data Supporting its Glioblastoma Immunotherapy Program at the ESMO Symposium on Immuno-Oncology - [at noodls] - CAMBRIDGE, Mass. and VANCOUVER, British Columbia, Nov. 4, 2015 (GLOBE NEWSWIRE) -- As previously announced, VBI Vaccines Inc. (NASDAQ:VBIV) ('VBI') and SciVac Therapeutics Inc. (TSX:VAC) (OTCQX:SVACF) ...
11/20/15 07:31 AMVBI VACCINES INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
11/06/15 07:54 AMVBI Vaccines to Present Update and New Data Supporting its RSV and CMV Vaccine Programs at the World Vaccine Congress Europe - [at noodls] - CAMBRIDGE, Mass. and VANCOUVER, British Columbia, Oct. 30, 2015 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ:VBIV) ('VBI') and SciVac Therapeutics Inc. (TSX:VAC) (OTCQX:SVACF) ('SciVac') will host a joint ...
About VBI Vaccines

VBI Vaccines logoVBI Vaccines Inc., formerly SciVac Therapeutics Inc., is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens. It is engaged in developing an experimental CMV vaccine using its eVLP vaccine platform. The vaccine is based on the CMV glycoprotein B antigen and is adjuvanted with aluminum phosphate. The eVLP vaccine technology allows for the expression of envelope glyco-proteins within a lipid-bilayer membrane of a VLP. It is developing a therapeutic vaccine candidate for glioblastoma multiforme (GBM). It is developing a vaccine to prevent respiratory syncytial virus (RSV) infection. It also offers Sci-B-Vac, which is a third-generation hepatitis B vaccine.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VBIV
  • CUSIP:
Key Metrics:
  • Previous Close: $4.00
  • 50 Day Moving Average: $4.07
  • 200 Day Moving Average: $4.07
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $130.78M
  • Current Quarter EPS Consensus Estimate: $-0.67 EPS
Additional Links:
VBI Vaccines (NASDAQ:VBIV) Chart for Friday, June, 24, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha